Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
20.16
+0.23 (1.15%)
At close: Jan 16, 2026, 4:00 PM EST
20.46
+0.30 (1.51%)
After-hours: Jan 16, 2026, 7:19 PM EST
Zenas BioPharma Revenue
Zenas BioPharma had revenue of $15.00M in the twelve months ending September 30, 2025. In the year 2024, Zenas BioPharma had annual revenue of $5.00M, down -90.00%.
Revenue (ttm)
$15.00M
Revenue Growth
-90.00%
P/S Ratio
56.37
Revenue / Employee
$115,385
Employees
130
Market Cap
1.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.00M | -45.00M | -90.00% |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionZBIO News
- 2 days ago - Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript - Seeking Alpha
- 12 days ago - Why Zenas BioPharma's Selloff Was Structurally Inevitable - Benzinga
- 13 days ago - Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor - Seeking Alpha
- 13 days ago - Zenas BioPharma Touts Phase 3 Win, But Stock Crashes - Benzinga
- 13 days ago - Zenas BioPharma's immune disorder drug meets main goal in late-stage trial - Reuters
- 13 days ago - Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) - GlobeNewsWire
- 4 weeks ago - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire